We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and... Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. Show more
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic...
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (βAIβ)-driven...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.06 | 1.1 | 0.95 | 37518 | 1.05374677 | CS |
4 | -0.06 | -5.35714285714 | 1.12 | 1.36 | 0.9 | 27113 | 1.1234521 | CS |
12 | -1.22 | -53.5087719298 | 2.28 | 2.8999 | 0.9 | 38837 | 1.51277003 | CS |
26 | -2.16 | -67.0807453416 | 3.22 | 3.72 | 0.9 | 58377 | 2.08637369 | CS |
52 | -10.2 | -90.5861456483 | 11.26 | 11.96 | 0.9 | 52229 | 3.31984764 | CS |
156 | -43.54 | -97.6233183857 | 44.6 | 45.4 | 0.9 | 415848 | 23.43044327 | CS |
260 | -61.14 | -98.2958199357 | 62.2 | 167 | 0.9 | 990716 | 45.69448532 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions